Comparative efficacy of therapeutic strategies for recurrent or refractory glioblastoma: a systematic review and network meta-analysis
Recurrent or refractory glioblastoma has a poor prognosis, and no universally accepted standard treatment has been established.
Recurrent or refractory glioblastoma has a poor prognosis, and no universally accepted standard treatment has been established.
The article evaluates and compares multiple therapies for recurrent or refractory glioblastoma in a network meta‑analysis, providing an updated synthesis of heterogeneous randomized evidence.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Glioma
- Glioblastoma Clinical Trials for New Treatments
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas
- EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma